Interestingly, the clinical trial of Epag in MDS was in combination with 5-Aza, known to upregulate TET2 and TET3 (48, 49), and thus Epag may have counteracted the effect of 5-Aza. The gene discussed is TET3; the disease is myelodysplastic syndrome.